Compare Cassava Sciences Inc (FLNA) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Hilton Hotels Corporation Common Stock trades at $326.56 (market cap $72.76B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 1846.7× Cassava Sciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| FLNA | HLT | |
|---|---|---|
Market Cap | $39.40M | $72.76B |
Volume | 759,018 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $350.22 |
52-Week Low | $0.68 | $256.96 |
Typical Hold Time | 37 Days | 138 Days |
Enterprise Value | -$43.28M | $85.78B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Hilton Worldwide (HLT) trades at $326.56, up 1.89% with a bullish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $12.04B in 2025, though valuation multiples like P/E of 47.47 appear elevated. Analyst consensus is strongly positive with 57% buy ratings and a $348.11 price target, while institutional investors have been increasing positions.
The outlook remains favorable given Hilton's strong brand positioning and global travel recovery, but risks include high debt levels and sensitivity to economic cycles. With technical indicators bullish and fundamental growth intact, HLT offers growth potential though current valuation requires careful monitoring of earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
